Adaptimmune Therapeutics (ADAP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist

0.662
+0.025+3.93%

Close Nov 22 16:00 ET

0.660
-0.002-0.24%

Post 20:01 ET

169.29MMarket Cap-3961P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Adaptimmune Therapeutics Analyst Ratings
BenzingaNov 19 12:41 ET · Ratings
European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading
MT NewswiresNov 19 11:18 ET
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Moomoo NewsNov 19 10:32 ET · Ratings
Promising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial Position
TipRanksNov 19 09:35 ET · Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
TipRanksNov 19 02:20 ET · Ratings
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Yahoo FinanceNov 16 07:19 ET

Comments

Trytosaveabit

Nov 13 16:14

Not to shabby!

$Adaptimmune Therapeutics (ADAP.US)$ Plus DATA to be presented for IGNYTE-ESO Trial of LETE-CEL in patients with SYNOVIAL SARCOMA! on 11/16/24 Saturday at CTOS annual meeting! ((((. Financial Results for the three and nine months ended September 30, 2024
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...

Stock_Drift

Nov 13 08:09

$Adaptimmune Therapeutics (ADAP.US)$

101674396

Oct 31 03:35

$Adaptimmune Therapeutics (ADAP.US)$ .. green when is the pre-market , will drop once open market!!!

Trytosaveabit

Sep 23 17:44

Newly filed 8K

$Adaptimmune Therapeutics (ADAP.US)$ Item 1.01Entry into a Material Definitive Agreement.
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...